PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Visiongain

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

World Hepatitis Treatment and Vaccine Market will Reach $8.7Bn in 2012 Predicts Visiongain Report - A new report by visiongain, a London-based business information provider, predicts that global revenues for hepatitis treatments and vaccines will reach $8.7 billion for 2012 - Visiongain.com
World Hepatitis Treatment and Vaccine Market will Reach $8.7Bn in 2012 Predicts Visiongain Report

 

NewswireToday - /newswire/ - London, United Kingdom, 2012/05/09 - A new report by visiongain, a London-based business information provider, predicts that global revenues for hepatitis treatments and vaccines will reach $8.7 billion for 2012 - Visiongain.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Between 2011 and 2022, the global market will grow with a CAGR of 8.7%, according to Hepatitis Treatments and Vaccines: World Market 2012-2022, published in May 2012.

Visiongain forecasts that oral antivirals will be the largest sector of the hepatitis treatment and vaccines market in 2022. The approval of direct-acting antivirals for treating hepatitis C throughout the coming 10 years will drive this growth. In 2011, interferon therapies, used for treating hepatitis B and C, accounted for 34.0% of the hepatitis market. The influence of these therapies in the market will decline, however, as increasing numbers of patients will be switched to oral antivirals in hepatitis C, particularly beyond the middle of the decade. Between 2011 and 2016, the interferons submarket will fall with a CAGR of -4.6%.

Richard Lang, a pharmaceutical industry analyst in visiongain, explains: “Currently, unmet needs exist in hepatitis C treatment. Drug developers are attempting to meet these needs, developing new direct-acting antivirals. The launch of the first interferon-free, oral regimens towards the middle of the decade will dramatically change the hepatitis market. Many companies, such as Abbott, Bristol-Myers Squibb and Gilead, are chasing this lucrative target. Companies that reach the market first will gain a significant advantage and market share.

“This study forecasts the future of ten leading brands in the hepatitis treatment and vaccines market. In 2011, only two blockbusters existed in the market - Baraclude for treating hepatitis B and Incivek for treating hepatitis C. Visiongain forecasts strong growth in revenue for both products early in the forecast period. However, patent expiries for Baraclude and increased competition for Incivek will cause revenue for both products to fall beyond 2016. GSK’s hepatitis vaccines will remain dominant in that submarket early in the forecast period. However, Engerix-B will face increasing competition from Dynavax Technologies’ Heplisav, expected to be approved in the US in 2013.”

This new report also discusses the leading national markets for hepatitis treatments and vaccines. In 2011, the US was the largest national market, with revenue there totalling $3.72 billion. The launch of new oral antivirals for hepatitis C, as well as the launch of Heplisav for hepatitis B prophylaxis, will drive growth in developed markets in the coming 10 years. Expanding vaccination programmes and rising wealth and disease awareness will stimulate growth in emerging national markets.

High rates of efficacy and barriers to resistance in leading treatments mean the hepatitis B market will grow strongly towards 2016. However, generic competition will affect the market towards the end of the period 2012 to 2022. Unmet treatment needs in hepatitis C, expanding vaccination programmes in emerging markets, and increased virus awareness and screening will ensure that the global hepatitis treatment and vaccine market will grow strongly between 2012 and 2022. Hepatitis Treatments and Vaccines: World Market 2012-2022 adds to visiongain’s range of analytical reports in the infectious disease sector.

For sample pages and further information concerning the visiongain report Hepatitis Treatments and Vaccines: World Market 2012-2022 please visit the website.

About visiongain
Visiongain (visiongain.com) is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Aviation and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Visiongain

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


World Hepatitis Treatment and Vaccine Market will Reach $8.7Bn in 2012 Predicts Visiongain Report

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Sara Peerun - Visiongain.com 
+44(0)20 7336 6100 sara.peerun[.]visiongainglobal.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Visiongain securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Visiongain / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)